GeoVax Labs, Inc. Warrants - GOVXW STOCK NEWS

GeoVax Labs, Inc. announces financial results for Q1 2023 and recent corporate highlights. The company is advancing its cancer gene therapy program and next-generation COVID-19 vaccine in Phase 2 clinical trials. Positive initial data was presented for the COVID-19 vaccine during the World Vaccine Congress. GeoVax has also made progress in developing a high-yield, high-capacity avian cell line system for manufacturing its vaccines. The company expanded its rights under its license agreement with City of Hope, granting it development and commercialization rights against orthopoxviruses. GeoVax reported a net loss of $4,037,916 for Q1 2023.

GeoVax Labs, Inc. (Nasdaq: GOVX) is participating as a sponsor in the 4th Symposium on Infectious Diseases in the Immunocompromised Host from April 30 to May 2, 2023, in Seattle, WA, hosted by Fred Hutchinson Cancer Center. The symposium will engage leaders and trainees in the field, focusing on various infectious diseases impacting vulnerable populations, including COVID-19, fungal infections, and more. CEO David Dodd emphasized the significance of innovative vaccine approaches, particularly mentioning the next-generation COVID-19 vaccine, GEO-CM04S1, currently in two Phase 2 trials. GeoVax aims to provide solutions for immunocompromised patients who are at higher risk for infections, reaffirming their commitment to developing advanced vaccine technologies.

GeoVax Labs, Inc. (Nasdaq: GOVX) is set to report its first quarter 2023 financial results on May 4, 2023, after market close. Following the report, management will conduct a live conference call and webcast to discuss the results and provide a business update, including a Q&A session. GeoVax specializes in immunotherapies and vaccines for cancer and infectious diseases. Its main oncology program, Gedeptin®, is currently undergoing a Phase 1/2 trial for advanced head and neck cancers. Additionally, its COVID-19 vaccine candidate, GEO-CM04S1, is in two Phase 2 trials targeting immunocompromised patients and evaluating its efficacy as a booster for healthy individuals. The company is led by a team with extensive experience in life sciences, aiming to create significant value for shareholders.

GeoVax Labs, Inc. (Nasdaq: GOVX) announced an expansion of its licensing agreement with the City of Hope (COH), now including development rights for vaccines targeting orthopoxviruses, such as Mpox and smallpox. This amendment enhances their COVID-19 vaccine program, specifically GEO-CM04S1, which is currently in two Phase 2 clinical trials. The CM04S1 vaccine employs a Modified Vaccinia Ankara (MVA) vector, aiming to provide robust immune responses against both SARS-CoV-2 and orthopoxviruses. GeoVax's Chairman, David Dodd, emphasized the potential public health benefits of their vaccine, especially for immunocompromised populations. The license expansion supports GeoVax's efforts to address global health threats posed by various viruses, potentially offering better protection in endemic regions.

GeoVax Labs, Inc. (GOVX) shared promising updates on its SARS-CoV-2 vaccine, GEO-CM04S1, during a presentation at the 23rd Annual World Vaccine Congress. Preliminary data from the ongoing Phase 2 clinical trial indicate that CM04S1 demonstrates high immunogenicity in immunocompromised patients undergoing hematological cancer treatments. The vaccine is designed to elicit robust antibody and T cell responses, targeting non-variable parts of the virus to provide better protection against emergent COVID-19 variants, including Omicron. The study also plans to compare CM04S1 with currently approved mRNA vaccines. The company aims to address the critical needs of high-risk populations that may not respond well to first-generation vaccines.

GeoVax Labs (Nasdaq: GOVX) announced significant progress in vaccine development against the Marburg virus, presenting data showing an 80% survival rate in cynomolgus macaques during a lethal challenge. This announcement, made at the 23rd Annual World Vaccine Congress, marks a critical advancement for GEO-MM01, which had previously shown complete protection in guinea pigs. Dr. Mark Newman expressed optimism about progressing the vaccine to clinical trials, while CEO David Dodd highlighted its potential against various infectious threats. The urgency for such solutions is underscored by recent outbreaks in Equatorial Guinea and Tanzania.

GeoVax Labs (Nasdaq: GOVX) announced its participation in the 23rd Annual World Vaccine Congress in Washington, DC, from April 3-6, 2023. The company will present data on its vaccine candidates, including details on the Sudan Ebola virus and its experimental COVID-19 vaccine, GEO-CM04S1. On April 5, Dr. Jason Comer will discuss vaccines against Sudan Ebola, focusing on efficacy studies done in collaboration with the National Institute of Allergy and Infectious Disease. On April 6, Dr. Don Diamond will highlight GEO-CM04S1's potential for immunocompromised patients, emphasizing its unique viral platform that elicits durable T cell responses.

GeoVax Labs, Inc. (GOVX) announced financial results for 2022, reporting a net loss of $14 million, down from $18.6 million in 2021. The company successfully raised approximately $35.4 million through equity offerings, boosting cash to $27.6 million. Key operational advancements include the Phase 1/2 expansion of Gedeptin® for advanced head and neck cancer and ongoing Phase 2 trials for the GEO-CM04S1 COVID-19 vaccine, showing robust immune responses. GeoVax also secured rights for NIH-MVA technology, aiming to be a primary supplier of MVA vaccines against Monkeypox and Smallpox. A conference call is scheduled for further discussions.